Aprea Therapeutics Inc

Compare

481 Followers

APRE Stock Chart & Stats

$1.45

-$0.03(-0.72%)

At close: Jan 08 4:00 PM EST

$1.45

-$0.03(-0.72%)

Day’s Range― - ―

52-Week Range$1.37 - $5.00

Previous CloseN/A

Volume2.88K

Average Volume (3M)55.77K

Market Cap

$9.15M

Enterprise Value-$5.52M

Total Cash (Recent Filing)$16.53M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.95

Next Earnings

Nov 06, 2025

EPS Estimate

-0.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.53

Shares Outstanding5,825,261

10 Day Avg. Volume84,633

30 Day Avg. Volume55,770

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.60

Enterprise Value/Revenue-8.14

Enterprise Value/Gross Profit-6.74

Enterprise Value/Ebitda0.37

Forecast

1Y Price Target

$10.00

Price Target Upside589.66% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Strategy ExecutionThe ATRN-119 update is a milestone for the company and continued demonstration of management's execution of its clinical strategy for the synthetic lethality drug pipeline.

Drug Development ProgressAprea's WEE1i and ATRi candidates have continued to make progress in early stage studies and management continues to execute on its development strategy.

Unique Drug StructuresAprea's ATRi and WEE1i have very different structures from other molecules in the space, providing a unique approach.

Bears Say

Industry ChallengesIssues in the synthetic lethality space, particularly for companies like Repare and Zentalis, cast a shadow over Aprea.

Market HeadwindsAprea, like many small biotechs, has been pressured by broad market headwinds and a lack of significant catalysts.

Market-Driven Share Price DeclineAprea's share price has pulled back to near an all-time low, driven by factors unrelated to the synthetic lethality pipeline.

Aprea Therapeutics News

Aprea Therapeutics provides update from ACESOT-1051 t rial

Aprea Therapeutics (APRE) provided an update on the ongoing Phase 1 ACESOT-1051 study. The latest results show that,...

8d ago

APRE

Aprea Therapeutics establishes RP2D for ATRN-119

Aprea Therapeutics (APRE) announced that it has determined the recommended Phase 2 dose, RP2D, of 1,100 mg once...

17d ago

APRE

Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors

Aprea Therapeutics, Inc. (($APRE)) announced an update on their ongoing clinical study. Aprea Therapeutics, Inc. is conducting a...

4d ago

APRE

Aprea Therapeutics Advances with Phase 1 Study of APR-1051 in Solid Tumors

Aprea Therapeutics, Inc. (($APRE)) announced an update on their ongoing clinical study. Aprea Therapeutics, Inc. is conducting a...

4d ago

APRE

Aprea Therapeutics Reports Promising Trial Results for APR-1051

The latest update is out from Aprea Therapeutics ( ($APRE) ). On October 24, 2025, Aprea Therapeutics announced...

8d ago

APRE

Aprea Therapeutics: Strategic Advancements and Unique Positioning Drive Buy Recommendation

Aprea Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

15d ago

APRE

Aprea Therapeutics Shifts Focus to Combination Therapies

Aprea Therapeutics ( ($APRE) ) has shared an announcement. On October 15, 2025, Aprea Therapeutics announced the recommended...

17d ago

APRE

Aprea Therapeutics Highlights Progress in Clinical Trials

Aprea Therapeutics ( ($APRE) ) has provided an announcement. On September 8, 2025, Aprea Therapeutics updated its corporate...

2M ago

APRE

Positive Outlook for Aprea Therapeutics: Promising Progress in WEE1i and ATRi Candidates Amidst Challenges

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Aprea Therapeutics. The associated price target...

3M ago

APRE

Aprea Therapeutics Reports Promising Q2 2025 Results

Aprea Therapeutics, Inc. ( ($APRE) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

APRE

Aprea Therapeutics Reports Q2 2025 Financial Results

Aprea Therapeutics ( ($APRE) ) has issued an announcement. On August 12, 2025, Aprea Therapeutics reported its financial...

3M ago

APRE

Aprea Therapeutics reports Q2 EPS (53c) vs. (58c) last year

Reports Q2 revenue $118,111 vs. $561,574 last year. “We are pleased with our progress in 2025, as emerging...

3M ago

APRE

Aprea Therapeutics sees cash runway into 2Q26

As of June 30, 2025, the Company reported cash and cash equivalents of $16.5 million compared to $22.8...

3M ago

APRE

Aprea Therapeutics announces new preclinical data, update on APR-1051

Aprea Therapeutics (APRE) announced new preclinical data and a clinical update on APR-1051, the Company’s next-generation oral WEE1...

4M ago

APRE

APRE FAQ

What was Aprea Therapeutics Inc’s price range in the past 12 months?

Aprea Therapeutics Inc lowest stock price was $1.37 and its highest was $5.00 in the past 12 months.

What is Aprea Therapeutics Inc’s market cap?

Aprea Therapeutics Inc’s market cap is $9.15M.

When is Aprea Therapeutics Inc’s upcoming earnings report date?

Aprea Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 5 days.

How were Aprea Therapeutics Inc’s earnings last quarter?

Aprea Therapeutics Inc released its earnings results on Aug 12, 2025. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.711 by $0.181.

Is Aprea Therapeutics Inc overvalued?

According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aprea Therapeutics Inc pay dividends?

Aprea Therapeutics Inc does not currently pay dividends.

What is Aprea Therapeutics Inc’s EPS estimate?

Aprea Therapeutics Inc’s EPS estimate is -0.34.

How many shares outstanding does Aprea Therapeutics Inc have?

Aprea Therapeutics Inc has 5,825,261 shares outstanding.

What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?

Aprea Therapeutics Inc reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.711. Following the earnings report the stock price went up 0.592%.

Which hedge fund is a major shareholder of Aprea Therapeutics Inc?

Currently, no hedge funds are holding shares in APRE

Company Description

Aprea Therapeutics Inc

Aprea Therapeutics (APRE) is a biotechnology company focused on developing and commercializing novel cancer therapeutics. The company is primarily engaged in the discovery and development of small molecule therapies that reactivate mutant tumor suppressor protein p53, which is often inactivated in a variety of cancers. Aprea's core product pipeline includes drug candidates for the treatment of hematologic malignancies and solid tumors, leveraging its proprietary technology to address unmet medical needs in oncology.

Aprea Therapeutics (APRE) Earnings & Revenues

Historic Earnings Reports

APRE Stock 12 Month Forecast

Average Price Target

$10.00

▲(589.66% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.46,2.1169230769230767,2.7738461538461534,3.4307692307692306,4.087692307692308,4.7446153846153845,5.401538461538461,6.058461538461538,6.715384615384615,7.372307692307691,8.029230769230768,8.686153846153845,9.343076923076922,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.46,2.1169230769230767,2.7738461538461534,3.4307692307692306,4.087692307692308,4.7446153846153845,5.401538461538461,6.058461538461538,6.715384615384615,7.372307692307691,8.029230769230768,8.686153846153845,9.343076923076922,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.46,2.1169230769230767,2.7738461538461534,3.4307692307692306,4.087692307692308,4.7446153846153845,5.401538461538461,6.058461538461538,6.715384615384615,7.372307692307691,8.029230769230768,8.686153846153845,9.343076923076922,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.35,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.25,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.77,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >